Posters

Prospective evaluation of a Schlemm’s canal microstent for treatment of primary angle-closure glaucoma in combination with phacoemulsification

Poster Details

First Author: R.Ang PHILIPPINES

Co Author(s):                        

Abstract Details

Purpose:

To assess preliminary safety and effectiveness of the Hydrus Microstent (Ivantis) implanted in Schlemm’s canal during cataract surgery for the treatment of primary angle closure glaucoma (PACG)

Setting:

Asian Eye Institute, Makati City, Philippines

Methods:

21 eyes from 21 subjects with cataract and PACG with IOP >21 mmHg on ³1 glaucoma medication or ³24 mmHg on no medications were treated with phacoemulsification and Hydrus Microstent. Goniosynecialysis (1-2 clock hours) was performed in the nasal hemisphere if needed to expose the trabecular meshwork (TM) prior to microstent insertion. Follow-up was conducted for 1 year postoperative.

Results:

Study patients were 100% Asian, 75% female and mean age was 66.8+/-7.2 years. Gonioscopy showed 82% of the angle was closed prior to surgery. Mean preoperative IOP 25.56+/-6.2 mm Hg and 1.4+/-1.3 medications. Device implant was successful in 20/21 subjects, 65% required goniosynechialysis to expose the TM prior to microstent insertion. At 6 months, mean IOP was 14.4+/-3.4 mm Hg and there were 0 medications in use (p<0.001 vs. baseline for IOP and medications). The device inlet remained visible and patent despite narrow or closed angle. There were no serious adverse events or complications.

Conclusions:

The Hydrus Microstent was associated with clinically and statistically significant reduction in IOP and medication when implanted during cataract surgery in PACG.  Through 6 months follow-up, the inlet remained open to the anterior chamber. There were no significant adverse safety findings.

Financial Disclosure:

... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented